Compare KRYS & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | TWST |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 9.2B |
| IPO Year | 2017 | 2018 |
| Metric | KRYS | TWST |
|---|---|---|
| Price | $347.00 | $127.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $297.60 | $46.88 |
| AVG Volume (30 Days) | 200.3K | ★ 1.5M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | 63.89 |
| EPS | ★ 3.62 | N/A |
| Revenue | ★ $389,130,000.00 | $376,572,000.00 |
| Revenue This Year | $38.74 | $18.91 |
| Revenue Next Year | $32.53 | $15.07 |
| P/E Ratio | $96.16 | ★ N/A |
| Revenue Growth | ★ 33.94 | 20.32 |
| 52 Week Low | $145.46 | $23.30 |
| 52 Week High | $382.54 | $155.44 |
| Indicator | KRYS | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 48.23 | 50.46 |
| Support Level | $289.36 | $115.28 |
| Resistance Level | $382.33 | $155.44 |
| Average True Range (ATR) | 11.24 | 8.91 |
| MACD | -0.73 | -3.36 |
| Stochastic Oscillator | 28.36 | 18.38 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.